ALT vs VKTX
ALT: A clinical-stage biopharmaceutical company developing dual-agonist peptide therapeutics targeting the massive obesity and metabolic disease markets. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | ALT | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.81 | $37.31 | |
| Market cap as of 2026-07-23 | $546M | $4.3B | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| Net margin as of 2026-07-23 | -214861.0% | n/a | |
| Gross margin as of 2026-07-23 | +100.5% | n/a | |
| Operating margin as of 2026-07-23 | -230461.0% | n/a | |
| ROE as of 2026-07-23 | -42.6% | -71.3% | ALT higher |
| ROA as of 2026-07-23 | -35.6% | -65.3% | ALT higher |
| Debt / equity as of 2026-07-23 | 0.12 | 0.00 | VKTX lower |
| Revenue growth (YoY) as of 2026-07-23 | +80.0% | n/a | |
| Beta as of 2026-07-23 | 0.14 | 0.65 | |
| 1-year return as of 2026-07-22 close | -30.4% | +16.2% | VKTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.